Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer

R. Wiebringhaus, M. Pecoraro, HA. Neubauer, K. Trachtová, B. Trimmel, M. Wieselberg, J. Pencik, G. Egger, C. Krall, R. Moriggl, M. Mann, B. Hantusch, L. Kenner

. 2021 ; 13 (23) : . [pub] 20211130

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22001170

Grant support
FA791A0906.FFG COMET Competence Center CBmed - Center for Biomarker 326 Research in Medicine
P26011 FWF Austrian Science Fund

We aimed to identify novel markers for aggressive prostate cancer in a STAT3-low proteomics-derived dataset of mitochondrial proteins by immunohistochemical analysis and correlation with transcriptomic data and biochemical recurrence in a STAT3 independent PCa cohort. Formalin-fixed paraffin-embedded tissue (FFPE) sample selection for proteomic analysis and tissue-microarray (TMA) generation was conducted from a cohort of PCa patients. Retrospective data analysis was performed with the same cohort. 153 proteins differentially expressed between STAT3-low and STAT3-high samples were identified. Out of these, 46 proteins were associated with mitochondrial processes including oxidative phosphorylation (OXPHOS), and 45 proteins were upregulated, including NDUFS1/ATP5O. In a STAT3 independent PCa cohort, high expression of NDUFS1/ATP5O was confirmed by immunocytochemistry (IHC) and was significantly associated with earlier biochemical recurrence (BCR). mRNA expression levels for these two genes were significantly higher in intra-epithelial neoplasia and in PCa compared to benign prostate glands. NDUFS1/ATP5O levels are increased both at the mRNA and protein level in aggressive PCa. Our results provide evidence that NDUFS1/ATP5O could be used to identify high-risk PCa patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001170
003      
CZ-PrNML
005      
20220112153516.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13236036 $2 doi
035    __
$a (PubMed)34885151
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wiebringhaus, Robert $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria $u Department of Otolaryngology, University Hospital, LMU Munich, 81377 Munich, Germany
245    10
$a Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer / $c R. Wiebringhaus, M. Pecoraro, HA. Neubauer, K. Trachtová, B. Trimmel, M. Wieselberg, J. Pencik, G. Egger, C. Krall, R. Moriggl, M. Mann, B. Hantusch, L. Kenner
520    9_
$a We aimed to identify novel markers for aggressive prostate cancer in a STAT3-low proteomics-derived dataset of mitochondrial proteins by immunohistochemical analysis and correlation with transcriptomic data and biochemical recurrence in a STAT3 independent PCa cohort. Formalin-fixed paraffin-embedded tissue (FFPE) sample selection for proteomic analysis and tissue-microarray (TMA) generation was conducted from a cohort of PCa patients. Retrospective data analysis was performed with the same cohort. 153 proteins differentially expressed between STAT3-low and STAT3-high samples were identified. Out of these, 46 proteins were associated with mitochondrial processes including oxidative phosphorylation (OXPHOS), and 45 proteins were upregulated, including NDUFS1/ATP5O. In a STAT3 independent PCa cohort, high expression of NDUFS1/ATP5O was confirmed by immunocytochemistry (IHC) and was significantly associated with earlier biochemical recurrence (BCR). mRNA expression levels for these two genes were significantly higher in intra-epithelial neoplasia and in PCa compared to benign prostate glands. NDUFS1/ATP5O levels are increased both at the mRNA and protein level in aggressive PCa. Our results provide evidence that NDUFS1/ATP5O could be used to identify high-risk PCa patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pecoraro, Matteo $u Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
700    1_
$a Neubauer, Heidi A $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
700    1_
$a Trachtová, Karolína $u Central European Institute of Technology, Masaryk University, 60177 Brno, Czech Republic $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, 1090 Vienna, Austria $u Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Trimmel, Bettina $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Wieselberg, Maritta $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Pencik, Jan $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Egger, Gerda $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria $u Ludwig Boltzmann Institute Applied Diagnostics, 1090 Vienna, Austria
700    1_
$a Krall, Christoph $u Institute for Statistics, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Moriggl, Richard $u Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
700    1_
$a Mann, Matthias $u Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
700    1_
$a Hantusch, Brigitte $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, 1090 Vienna, Austria $u Center for Biomarker Research in Medicine (CBmed), 8010 Graz, Austria $u Unit for Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 23 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34885151 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20220112153512 $b ABA008
999    __
$a ind $b bmc $g 1745388 $s 1152317
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 23 $e 20211130 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a FA791A0906.FFG $p COMET Competence Center CBmed - Center for Biomarker 326 Research in Medicine
GRA    __
$a P26011 $p FWF Austrian Science Fund
LZP    __
$a Pubmed-20220107

Find record

Citation metrics

Archiving options